Effects of elgodipine in vascular smooth muscle

Tejerina, Teresa; González, Pamela; Galiano, Alessandro; Alguacil, Mario; Miguel, B. De

doi:10.1016/0014-2999(90)93460-8

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the elgodipine plasma concentration profile (HPLC), three phases of elimination with half-life times of less than I hour, between 3 and 7 hours, and between 10 and 24 hours may be distinguished, indicating a "shallow" and a "deep" compartment. The hemodynamic data indicate an intermediate pharmacodynamic profile of elgodipine, lying between that of other dihydropyridines and that of compounds such as verapamil or diltiazem.Elgodipine (CAS 119413-55-7) is a photoresistant 1,4-dihydropyridine calcium channel antagonist that shows relative selectivity for vascular smooth muscle [1,2]. During coronary angiography in humans, elgodipine (15 ~Lg/kg iv) induced coronary vasodilation and lowered systemic blood pressure; heart rate, myocardial oxygen consumption, and left ventricular contractility were unaltered [3].…”

mentioning

confidence: 99%

“…Elgodipine (CAS 119413-55-7) is a photoresistant 1,4-dihydropyridine calcium channel antagonist that shows relative selectivity for vascular smooth muscle [1,2]. During coronary angiography in humans, elgodipine (15 ~Lg/kg iv) induced coronary vasodilation and lowered systemic blood pressure; heart rate, myocardial oxygen consumption, and left ventricular contractility were unaltered [3].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Hemodynamic effects of intravenous elgodipine in coronary artery disease during rest and exercise, and basic pharmacokinetic parameters

Silke

Motte²,

Spiers

et al. 1996

Cardiovasc Drug Ther

View full text Add to dashboard Cite

Using an echo-Doppler method (Quantascope), the hemodynamic profile of the calcium channel antagonist elgodipine (64 micrograms/kg, i.v.) was investigated in 22 patients with angina pectoris at rest and during exercise. A placebo control was used. At rest, elgodipine significantly decreased systemic vascular resistance as well as systolic and diastolic blood pressure, while increasing cardiac output and stroke volume. During supine bicycle exercise the constant workload, elgodipine significantly increased cardiac output and stroke volume, and decrease the rate-pressure-product (double product); the exercise systolic blood pressure was decreased without change in the diastolic component. Elgodipine significantly reduced the incidence and severity (self-rated pain score) of exercise-induced anginal systems. Heart rate was not affected by elgodipine, either at rest or during exercise. In particular, no negative inotropy could be inferred from the echo-Doppler data. In the elgodipine plasma concentration profile (HPLC), three phases of elimination with half-life times of less than 1 hour, between 3 and 7 hours, and between 10 and 24 hours may be distinguished, indicating a "shallow" and a "deep" compartment. The hemodynamic data indicate an intermediate pharmacodynamic profile of elgodipine, lying between that of other dihydropyridines and that od compounds such as verapamil or diltiazem.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Hemodynamic effects of intravenous elgodipine in coronary artery disease during rest and exercise, and basic pharmacokinetic parameters

Silke

Motte²,

Spiers

et al. 1996

Cardiovasc Drug Ther

View full text Add to dashboard Cite

show abstract

Application of quantitative coronary angiography in the study of pharmacologically induced coronary vasomotion

Suryapranata¹,

Serruys²

1994

Quantitative Coronary Angiography in Clinical Practice

View full text Add to dashboard Cite

Hemodynamic and antiischemic effects of intravenous elgodipine, a new dihydropyridine calcium channel blocker, in patients with chronic stable angina

Kühn

Carlsson

Miketic

et al. 1995

Cardiovasc Drug Ther

View full text Add to dashboard Cite

Elgodipine is a new second-generation dihydropyridine calcium antagonist. Its hemodynamic and antiischemic properties were evaluated in a single-blind, placebo-controlled trial in 22 males with chronic stable angina. Coronary artery disease was angiographically confirmed. Measurements were performed with a Swan-Ganz thermodilution catheter during a 30-minute period of rest and before the end of a 4-minute bicycle exercise test at maximum individual workload, both with placebo (IV infusion of 5 ml saline over 30 minutes) and elgodipine (10 micrograms/kg/2 min bolus IV, then IV infusion of 1 micrograms/kg/min for 28 minutes. Elgodipine caused very similar hemodynamic changes at rest and during exercise. Its major hemodynamic modification was the marked decrease in systemic vascular resistance, which was accompanied by an increase in cardiac index and stroke volume. Mean arterial blood pressure was slightly reduced, whereas the opposite small increase in heart rate meant that the double product remained unchanged. Contrary to resting conditions, pulmonary capillary wedge pressure, pulmonary artery pressures, pulmonary vascular resistance, and mean right atrial pressure remained normal or increased to a lesser extent during exercise after elgodipine. After elgodipine ischemic ST depression during exercise was diminished, and 11 of 16 assessable patients remained free from angina pectoris. We conclude that elgodipine is an efficacious antianginal drug. Its major mechanism of action is lowering of systemic vascular resistance. Thus elgodipine improves systolic cardiac function in patients with chronic stable angina and may delay the onset of ischemic diastolic dysfunction during exercise, as indicated by a normal left ventricular end-diastolic pressure (LVEDP). The data also suggest an improvement in coronary blood flow during exercise.

show abstract

Effects of elgodipine in vascular smooth muscle

Cited by 4 publications

References 0 publications

Hemodynamic effects of intravenous elgodipine in coronary artery disease during rest and exercise, and basic pharmacokinetic parameters

Hemodynamic effects of intravenous elgodipine in coronary artery disease during rest and exercise, and basic pharmacokinetic parameters

Application of quantitative coronary angiography in the study of pharmacologically induced coronary vasomotion

Hemodynamic and antiischemic effects of intravenous elgodipine, a new dihydropyridine calcium channel blocker, in patients with chronic stable angina

Contact Info

Product

Resources

About